Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Decreases By 36.9%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large decline in short interest during the month of August. As of August 15th, there was short interest totaling 1,130,000 shares, adeclineof36.9% from the July 31st total of 1,790,000 shares. Based on an average trading volume of 11,770,000 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 11,770,000 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Windtree Therapeutics

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned about 1.08% of Windtree Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 29.33% of the company’s stock.

Windtree Therapeutics Price Performance

NASDAQ:WINT opened at $0.07 on Friday. Windtree Therapeutics has a 1 year low of $0.06 and a 1 year high of $195.00. The stock’s 50 day simple moving average is $0.57 and its two-hundred day simple moving average is $1.10. The company has a market cap of $2.14 million, a price-to-earnings ratio of 0.00 and a beta of 0.57.

Windtree Therapeutics (NASDAQ:WINT) last released its quarterly earnings data on Tuesday, August 19th. The company reported ($3.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($99.00) by $95.94. As a group, analysts anticipate that Windtree Therapeutics will post -5.66 EPS for the current year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.